Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Prepaid Assets (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Prepaid Assets for 5 consecutive years, with $1.9 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Prepaid Assets fell 12.87% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2024, down 12.87%, and an annual FY2024 reading of $1.9 million, down 12.87% over the prior year.
  • Prepaid Assets was $1.9 million for Q4 2024 at Cytek Biosciences, down from $2.2 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $13.0 million in Q4 2022 and bottomed at $162000.0 in Q4 2020.
  • Average Prepaid Assets over 5 years is $3.6 million, with a median of $2.1 million recorded in 2022.
  • Peak annual rise in Prepaid Assets hit 15.03% in 2023, while the deepest fall reached 82.79% in 2023.
  • Year by year, Prepaid Assets stood at $162000.0 in 2020, then soared by 3855.56% to $6.4 million in 2021, then surged by 102.15% to $13.0 million in 2022, then tumbled by 82.79% to $2.2 million in 2023, then fell by 12.87% to $1.9 million in 2024.
  • Business Quant data shows Prepaid Assets for CTKB at $1.9 million in Q4 2024, $2.2 million in Q4 2023, and $2.2 million in Q3 2023.